Head-to-head evidence
BMS-986322 vs ICP-488
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
BMS-986322
Developed by Bristol-Myers Squibb and partners
NCT05730725 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.
ICP-488
Developed by Beijing InnoCare Pharma Tech Co.
NCT06109818 · Phase 2 · completed
The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.
Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BMS-986322's landscape · ICP-488's landscape